Tag: NervGen Pharma
NVG-291 spinal cord injury treatment enters Phase II clinical trials
In a groundbreaking development for paralysed people, the revolutionary NVG-291 treatment for spinal cord injury is set to undergo Phase II clinical trials.
It...
NervGen’s NVG-291 brings New Hope for People With Spinal Cord Injuries
(NAPSI)—If you or someone you care about is ever among the approximately 17,700 Americans who each year, according to The Journal of American Medical...
6 key developments in spinal cord injury research
Here are six key updates in the treatment of spinal cord injuries in the past six months:
The Tim and Caroline Reynolds Center for Spinal...
